businesspress24.com - The Law Firm of Levi & Korsinsky Notifies Investors With Losses on Their Investment in K-V Pharm
 

The Law Firm of Levi & Korsinsky Notifies Investors With Losses on Their Investment in K-V Pharmaceutical Company of Class Action Lawsuit and the Deadline of December 19, 2011 to Seek a Lead Plaintiff Position

ID: 1049613

(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 10/25/11 -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Missouri on behalf of purchasers of K-V Pharmaceutical Company ("K-V" or the "Company") (NYSE: KV-A) (NYSE: KV-B) common stock between February 14, 2011 and April 4, 2011.

For more information, click here: .

The complaint alleges that K-V and certain of its officers and directors issued materially false and misleading statements regarding the miscarriage prevention drug "Makena." In particular, the complaint alleges that K-V made misleading statements indicating that the Company would expand access to Makena to low-income and other at-risk groups. According to the complaint, contrary to these statements, K-V increased the price of Makena 1490% to $1500 per injection, thus limiting the affordability of the treatment. Furthermore, the complaint alleges that K-V issued misleading statements indicating that the FDA had granted K-V the exclusive distribution rights over "Makena" and that the agency would enforce said rights by preventing the distribution of generic compounds by K-V's competitors. On March 30, 2011, the FDA issued a press release indicated that it would not "take enforcement action against pharmacies" that sold the generic form.

If you are a member of the class and suffered a loss in K-V stock, you have until December 19, 2011 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at or by telephone at (877) 363-5972, or visit .

Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.







CONTACT:
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 15th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Dallas Criminal Attorneys of the Lassiter Law Office Announce Expansion of Services to Neighboring Communities
Fish & Richardson Secures $32 Million Appellate Win for Video Game Legend Richard Garriott
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 25.10.2011 - 08:39 Uhr
Sprache: Deutsch
News-ID 1049613
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

NEW YORK, NY


Phone:

Kategorie:

Legal


Anmerkungen:


Diese Pressemitteilung wurde bisher 96 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"The Law Firm of Levi & Korsinsky Notifies Investors With Losses on Their Investment in K-V Pharmaceutical Company of Class Action Lawsuit and the Deadline of December 19, 2011 to Seek a Lead Plaintiff Position
"
steht unter der journalistisch-redaktionellen Verantwortung von

Levi & amp; Korsinsky, LLP (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Levi & amp; Korsinsky, LLP



 

Who is online

All members: 10 572
Register today: 2
Register yesterday: 0
Members online: 0
Guests online: 100


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.